Physician profile
Sheldon A Ross
NPI 1932200326
$572.83
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $217 · 2021: $128 · 2022: $77.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $226.79 | 2019-2022 | |
| Organogenesis INC. | $179.40 | 2019-2022 | |
| Misonix INC | $126.40 | 2020-2021 | |
| Kci USA, INC. | $25.37 | 2020 | |
| Biotissue Holdings INC. | $14.87 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.